These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 27784744)

  • 1. Alox5 Blockade Eradicates JAK2V617F-Induced Polycythemia Vera in Mice.
    Chen Y; Shan Y; Lu M; DeSouza N; Guo Z; Hoffman R; Liang A; Li S
    Cancer Res; 2017 Jan; 77(1):164-174. PubMed ID: 27784744
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-inflammatory cytokines hepatocyte growth factor and interleukin-11 are over-expressed in Polycythemia vera and contribute to the growth of clonal erythroblasts independently of JAK2V617F.
    Boissinot M; Cleyrat C; Vilaine M; Jacques Y; Corre I; Hermouet S
    Oncogene; 2011 Feb; 30(8):990-1001. PubMed ID: 21042281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F.
    Zaleskas VM; Krause DS; Lazarides K; Patel N; Hu Y; Li S; Van Etten RA
    PLoS One; 2006 Dec; 1(1):e18. PubMed ID: 17183644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A drug targeting 5-lipoxygenase enhances the activity of a JAK2 inhibitor in CD34
    Chen Y; Zhao H; Luo J; Liao Y; Tan K; Hu G
    Oncol Lett; 2021 May; 21(5):351. PubMed ID: 33747208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Application of PRV-1 mRNA expression level and JAK2V617F mutation for the differentiating between polycytemia vera and secondary erythrocytosis and assessment of treatment by interferon or hydroxyurea.
    Tutaeva V; Misurin AV; Michiels JJ; Rozenberg JM; Sokolova MA; Ivanova VL; Kolosheinova TI; Manakova TE; Levina AA; Semenova EA; Khoroshko ND
    Hematology; 2007 Dec; 12(6):473-9. PubMed ID: 17852451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Critical requirement for Stat5 in a mouse model of polycythemia vera.
    Yan D; Hutchison RE; Mohi G
    Blood; 2012 Apr; 119(15):3539-49. PubMed ID: 22144185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Addiction to DUSP1 protects JAK2V617F-driven polycythemia vera progenitors against inflammatory stress and DNA damage, allowing chronic proliferation.
    Stetka J; Vyhlidalova P; Lanikova L; Koralkova P; Gursky J; Hlusi A; Flodr P; Hubackova S; Bartek J; Hodny Z; Divoky V
    Oncogene; 2019 Jul; 38(28):5627-5642. PubMed ID: 30967632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of vorinostat in a murine model of polycythemia vera.
    Akada H; Akada S; Gajra A; Bair A; Graziano S; Hutchison RE; Mohi G
    Blood; 2012 Apr; 119(16):3779-89. PubMed ID: 22408262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevated levels of mast cells are involved in pruritus associated with polycythemia vera in JAK2V617F transgenic mice.
    Jin X; Zhao W; Kirabo A; Park SO; Ho WT; Sayeski PP; Zhao ZJ
    J Immunol; 2014 Jul; 193(2):477-84. PubMed ID: 24920845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polycythemia vera is not initiated by JAK2V617F mutation.
    Nussenzveig RH; Swierczek SI; Jelinek J; Gaikwad A; Liu E; Verstovsek S; Prchal JF; Prchal JT
    Exp Hematol; 2007 Jan; 35(1):32-8. PubMed ID: 17198871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Involvement of various hematopoietic-cell lineages by the JAK2V617F mutation in polycythemia vera.
    Ishii T; Bruno E; Hoffman R; Xu M
    Blood; 2006 Nov; 108(9):3128-34. PubMed ID: 16757685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-time bioluminescence imaging of polycythemia vera development in mice.
    Ma Y; Zhao S; Zhu J; Bettano KA; Qu X; Marshall CG; Young JR; Kohl NE; Scott ML; Zhang W; Wang Y
    Biochim Biophys Acta; 2009 Nov; 1792(11):1073-9. PubMed ID: 19715759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transcriptional profiling of polycythemia vera identifies gene expression patterns both dependent and independent from the action of JAK2V617F.
    Berkofsky-Fessler W; Buzzai M; Kim MK; Fruchtman S; Najfeld V; Min DJ; Costa FF; Bischof JM; Soares MB; McConnell MJ; Zhang W; Levine R; Gilliland DG; Calogero R; Licht JD
    Clin Cancer Res; 2010 Sep; 16(17):4339-52. PubMed ID: 20601445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential NOD/SCID mouse engraftment of peripheral blood CD34+ cells and JAK2V617F clones from patients with myeloproliferative neoplasms.
    Fung TK; Cheung AM; Kwong YL; Liang R; Leung AY
    Leuk Res; 2010 Oct; 34(10):1390-4. PubMed ID: 20170959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Behavior of CD34+ cells isolated from patients with polycythemia vera in NOD/SCID mice.
    Ishii T; Zhao Y; Sozer S; Shi J; Zhang W; Hoffman R; Xu M
    Exp Hematol; 2007 Nov; 35(11):1633-40. PubMed ID: 17764815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined inhibition of Janus kinase 1/2 for the treatment of JAK2V617F-driven neoplasms: selective effects on mutant cells and improvements in measures of disease severity.
    Liu PC; Caulder E; Li J; Waeltz P; Margulis A; Wynn R; Becker-Pasha M; Li Y; Crowgey E; Hollis G; Haley P; Sparks RB; Combs AP; Rodgers JD; Burn TC; Vaddi K; Fridman JS
    Clin Cancer Res; 2009 Nov; 15(22):6891-900. PubMed ID: 19887489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Study of two tyrosine kinase inhibitors on growth and signal transduction in polycythemia vera.
    Gaikwad A; Prchal JT
    Exp Hematol; 2007 Nov; 35(11):1647-56. PubMed ID: 17976517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The JAK2V617F mutation in polycythemia vera and other myeloproliferative disorders: one mutation for three diseases?
    James C
    Hematology Am Soc Hematol Educ Program; 2008; ():69-75. PubMed ID: 19074061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacious intermittent dosing of a novel JAK2 inhibitor in mouse models of polycythemia vera.
    Kraus M; Wang Y; Aleksandrowicz D; Bachman E; Szewczak AA; Walker D; Xu L; Bouthillette M; Childers KM; Dolinski B; Haidle AM; Kopinja J; Lee L; Lim J; Little KD; Ma Y; Mathur A; Mo JR; O'Hare E; Otte RD; Taoka BM; Wang W; Yin H; Zabierek AA; Zhang W; Zhao S; Zhu J; Young JR; Marshall CG
    PLoS One; 2012; 7(5):e37207. PubMed ID: 22623993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of JAK2V617F Mutation Burden on Disease Phenotype in Chinese Patients with JAK2V617F-positive Polycythemia Vera (PV) and Essential thrombocythemia (ET).
    Zhao S; Zhang X; Xu Y; Feng Y; Sheng W; Cen J; Wu D; Han Y
    Int J Med Sci; 2016; 13(1):85-91. PubMed ID: 26917989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.